CoChat

A phase Ib dose-escalation and expansion study of the BCL2 inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Abstract Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. Using a phase Ib 3 + 3 dose-escalation and expansion study design, 33 patients with ER and BCL2-positive metastatic disease (mean prior regimens, 2; range, 0–8) were treated with daily tamoxifen (20 mg) and venetoclax (200–800 mg). Apart from uncomplicated “on-target” lymphopenia, no dose-limiting toxicities or high-grade adverse events were observed in the escalation phase (15 patients), and 800 mg was selected as the recommended phase II dose (RP2D). In the expansion phase (18 patients), few high-grade treatment-related adverse events were observed. For 24 patients treated at the RP2D, the confirmed radiologic response rate was 54% and the clinical benefit rate was 75%. Treatment responses were preempted by metabolic responses (FDG-PET) at 4 weeks and correlated with serial changes in circulating tumor DNA. Radiologic responses (40%) and clinical benefit (70%) were observed in 10 patients with plasma-detected ESR1 mutations. Significance: In the first clinical study to evaluate venetoclax in a solid tumor, we demonstrate that combining venetoclax with endocrine therapy has a tolerable safety profile and elicits notable activity in ER and BCL2-positive metastatic breast cancer. These findings support further investigation of combination therapy for patients with BCL2-positive tumors. See related commentary by Drago et al., p. 323. This article is highlighted in the In This Issue feature, p. 305

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-18-1151

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Seymour, 2013, Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy show anti-tumor activity including complete remissions in high-risk relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (abstract 7018), Blood, 122, 429s

Cited by

See all 148

Metadata

Authors
Lok, S. W., Whittle, J. R., Vaillant, F., Teh, C. E., Lo, L. L., Policheni, A. N., Bergin, A. R. T., Desai, J., Ftouni, S., Gandolfo, L. C., Liew, D., Liu, H. K., Mann, G. B., Moodie, K., Murugasu, A., Pal, B., Roberts, A. W., Rosenthal, M. A., Shackleton, K., Silva, M. J., Siow, Z. R., Smyth, G. K., Taylor, L., Travers, A., Yeo, B., Yeung, M. M., Bujak, A. Z., Dawson, S.-J., Gray, D. H. D., Visvader, J. E., & Lindeman, G. J.
Affiliations
  • The Royal Melbourne Hospital (AU)
  • The University of Melbourne (AU)
  • Peter MacCallum Cancer Centre (AU)
  • Walter and Eliza Hall Institute of Medical Research (AU)
  • Austin Health (AU)
Corresponding author
Lindeman, Geoffrey J.
Venue
Cancer Discovery
Published
2019-03-01
Volume
9
Issue
3
Pages
354-369
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2902257786
Cited by
148
References
45
Citations by year
2026: 10 · 2025: 13 · 2024: 17 · 2023: 21 · 2022: 21 · 2021: 33 · 2020: 22 · 2019: 11
FWCI
15.97
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Monash University Research Portal (Monash University) (submittedVersion, other-oa)
Funders
  • National Health and Medical Research Council (1016701, 1040978, 1054618, 1078763, 1113133)
  • Victorian Cancer Agency (TRP13041, 13-035)
  • National Breast Cancer Foundation (NT-13-06)
  • NHMRC (1089072, 1090236, 1100807, 1058892, 1037230, 1078730)
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
venetoclax, tamoxifen, BCL-2 inhibitor, endocrine therapy, estrogen receptor-positive breast cancer, combination therapy, dose-limiting toxicity, circulating tumor DNA, ESR1 mutations, lymphopenia
MeSH terms
Circulating Tumor DNA, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Middle Aged, Neoplasm Metastasis, Sulfonamides, Tamoxifen, Tissue Distribution, Disease-Free Survival, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2, Estrogen Receptor alpha

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.